Barclays initiated coverage on Amgen with a new price target
$AMGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Barclays initiated coverage of Amgen with a rating of Equal Weight and set a new price target of $185.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/21/2026 | $366.00 | Hold | Canaccord Genuity |
| 3/10/2026 | $350.00 | Hold | Jefferies |
| 2/20/2026 | $185.00 | Equal Weight | Barclays |
| 1/20/2026 | $335.00 | Outperform → Mkt Perform | Bernstein |
| 1/7/2026 | $380.00 | Buy | UBS |
| 12/5/2025 | Hold → Buy | Erste Group | |
| 11/24/2025 | $318.00 | Hold | Truist |
| 11/13/2025 | $385.00 | Sector Outperform | Scotiabank |
4 - AMGEN INC (0000318154) (Issuer)
4 - AMGEN INC (0000318154) (Issuer)
4 - AMGEN INC (0000318154) (Issuer)
Canaccord Genuity initiated coverage of Amgen with a rating of Hold and set a new price target of $366.00
Jefferies initiated coverage of Amgen with a rating of Hold and set a new price target of $350.00
Barclays initiated coverage of Amgen with a rating of Equal Weight and set a new price target of $185.00
Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:
Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:
Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:
Organizational Changes Further Emphasize Integration of Biology and TechnologyTHOUSAND OAKS, Calif., April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of David M. Reese, M.D., executive vice president and Chief Technology Officer, effective June 30, 2026. Reese joined Amgen in 2005 as a clinical development leader in oncology and later served as executive vice president of Research and Development (R&D) from 2018 to 2023. During his tenure, he led approvals of numerous innovative medicines and biosimilars, advanced a robust pipeline of potential new therapies and strengthened discovery research capabilities. As inaugural chief technology officer, Reese encoura
Primary and Key Secondary Endpoints Met 77% of Patients Achieved Highly Statistically Significant Proptosis Response Study Showed Clinically Meaningful Reduction in Proptosis; Greater Than 3 mmTHOUSAND OAKS, Calif., April 6, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active Thyroid Eye Disease (TED). TEPEZZA OBI provides comparable efficacy to, and builds upon the success of, intravenous (IV) TEPEZZA, the first and only medicine approved for the treatment of TED, which has now treated more than
- Collaboration with Amgen to explore the clinical potential of Zai Lab's DLL3-targeting ADC, zocilurtatug pelitecan, in combination with Amgen's IMDELLTRA® - Amgen to sponsor and lead global Phase 1b study; Zai Lab to retain full ownership of zocilurtatug pelitecan Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced a global clinical trial collaboration with Amgen Inc. (NASDAQ:AMGN) to evaluate Zai Lab's investigational delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci, formerly ZL-1310), in combination with Amgen's IMDELLTRA® (tarlatamab-dlle), a DLL3-targeting Bispecific T-cell Engager (BiTE®) therapy in patients with extensive-st
4 - AMGEN INC (0000318154) (Reporting)
8-K - AMGEN INC (0000318154) (Filer)
DEFA14A - AMGEN INC (0000318154) (Filer)
DEFA14A - AMGEN INC (0000318154) (Filer)
Organizational Changes Further Emphasize Integration of Biology and TechnologyTHOUSAND OAKS, Calif., April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of David M. Reese, M.D., executive vice president and Chief Technology Officer, effective June 30, 2026. Reese joined Amgen in 2005 as a clinical development leader in oncology and later served as executive vice president of Research and Development (R&D) from 2018 to 2023. During his tenure, he led approvals of numerous innovative medicines and biosimilars, advanced a robust pipeline of potential new therapies and strengthened discovery research capabilities. As inaugural chief technology officer, Reese encoura
NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership TeamWill spearhead clinical advancement of the company's innovative NLRP3 inflammasome inhibitor portfolioBrings deep clinical leadership in obesity and cardiometabolic diseases, with a proven track record guiding programs from early-stage development through Phase 3 and regulatory approval Philadelphia, PA, July 21, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appoi
Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary PreventionVESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha in High-Risk Patients, with Median 44 mg/dL LDL-C AchievedTHOUSAND OAKS, Calif., March 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that Repatha® (evolocumab), when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments, reduced the risk of first major adverse cardiovascular (CV) events (MACE) in high-risk primary prevention patients without known significant atherosclerosis (buildup of plaque in the arteries) and with diabetes. The findings wer
THOUSAND OAKS, Calif., March 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the second quarter of 2026. The dividend will be paid on June 5, 2026, to all stockholders of record as of the close of business on May 15, 2026.About AmgenAmgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge
THOUSAND OAKS, Calif., Feb. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2025 versus the comparable periods in 2024. "Amgen delivered strong performance in 2025, with double-digit growth in revenues and earnings per share. We enter 2026 with momentum across a broad portfolio of medicines and a clear path towards advancing innovative therapies to deliver sustained long-term growth," said Robert A. Bradway, chairman and chief executive officer. Key results include: For the fourth quarter, total revenues increased 9% to $9.9 billion in comparison to the fourth quarter of 2024.Product sales grew 7%, driven by 10% volume gro
SC 13G/A - AMGEN INC (0000318154) (Subject)
SC 13G/A - AMGEN INC (0000318154) (Subject)
SC 13D - AMGEN INC (0000318154) (Filed by)